Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 18/20 | 0.62 |
| ▸ | PRKD2 | Q9BZL6 | 10/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328379 | 1.00 | PRKCZ (0.62) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL23328115 | 1.00 | PRKCZ (0.62) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL30175611 | 1.00 | PRKCZ (0.62) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL25043849 | 0.97 | PRKCZ (0.67) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL30175675 | 0.97 | PRKCZ (0.67) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL25043297 | 0.97 | PRKCZ (0.67) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL30175674 | 0.97 | PRKCZ (0.67) | PRKCZPRKD2CCNT1CCNKCCNE1 | |
| SCHEMBL23328145 | 0.94 | PRKCZ (0.57) | PRKCZPRKD2BRD4 | |
| SCHEMBL23328179 | 0.94 | PRKCZ (0.57) | PRKCZPRKD2BRD4 | |
| SCHEMBL23328171 | 0.94 | PRKCZ (0.57) | PRKCZPRKD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2021084265-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | PRKCZ 875/4885PRKD2 314/4885CCNT1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.